Skip to main content

sovihep D

sovihep D

Description

The active substance is Sofosbuvir and Daclatasvir (sovihep d tablet), which is an inhibitor of the NS5A protein required for the synthesis of HCV.

The main purpose of the sovihep d is antiviral therapy. It is active in the fight against viral hepatitis C (genotypes 1, 2, 3, 4).

The essence of the impact is to block the development of HCV and its spread in the body of the carrier.

HCV exists in different forms known as genotypes.

Genotype 1 is the most common type of HCV genotype and sovihep d tablet is also the most difficult to treat using other treatments.

Mechanism of Action:

DCV is an HCV NS5A replication complex inhibitor.

This NS5A sovihep d  viral protein has enzymatic activity that is essential for HCV RNA replication and assembly.

In replication it appears to play a role in the formation of a membranous web along with viral protein NS4B, and this web provides a platform for replication.
The NS5A protein is composed of 3 domains;

Domains I and II are essential for HCV replication while the domain III seems to help the vision assembly.

The NS5A inhibitors have high antiviral sovihep d tablet potency but lower barrier to resistance development.

DCV acts as an NS5A inhibitor by binding within the first 100 amino acids of the amino terminus (i.e. domain 1) of the protein.

DCV results rapidly in serum HCV sovihep d  RNA drop by 2 logs within the first 6 h of administration, followed by a slower phase of decline, suggesting that it blocks vision assembly and release as well as viral RNA synthesis.
Dosage and administration

sovihep d tablet is given as a 60 mg oral dose once per day with or without food.

sovihep d should be administered at 60 mg/day or at 30 mg/day when a reduced dose is warranted.

Finally, sovihep d tablet dosage modification is not required in patients with liver failure Child-Pugh (CP) B or C, in the elderly or in patients with renal or hepatic impairment.

Side Effects

•Headache

•Unusual tiredness

•Nausea and Vomiting

• Diarrhea

• Anemia

•Severe skin rash and hives

•Dizziness

•Sleep disturbances

•Shortness of breath

•Chest pain or discomfort

•Mental confusion

•Memory problems



Warning and Contradictions:

sovihep d tablet 60 Tablet may interact with many other medicines and may cause severe adverse effects. Hence, it is advised that you inform the doctor about all your current medicines including any herbs and supplements before beginning treatment with this medicine.

Adverse Events:

The most commonly reported AEs were (≥5%): headache (14%), fatigue (14%), nausea (8%), and diarrhea (5%)

CONTACT US :

EMAIL ID : millionhealthpharmaceuticals@gmail.com

PHONE NO : +91-9940472902

WEBSITE URL : https://pillsbag.com/products/sovihep-d

KEYWORDS : sovihep d,sovihep d tablet, sovihep d price in India



Comments

Popular posts from this blog

Xbira 250mg : Abiraterone acetate Cipla Uses, Side Effect, Price india

Drug profile of Xbira xbira 250mg tablet  are containing an active component known as Abiraterone acetate which exhibits anti-tumor activity against prostate cancer. xbira 250mg  Cipla is a derivative of androstene, which involves in the prohibition process of steroid 17 alpha hydroxylase and containing anti-neoplastic activity. Abiraterone acetate  xbira  is an oral tablet which is an active acetate ester form of steroidal compound known as Abiraterone with anti-androgenic activity. Abiraterone acetate  xbira 250mg tablet  is involved by interfering with testosterone activity by inhibiting the synthesis. PRODUCT DETAILS Brand name: Xbira Active substance: Abiraterone acetate Strength: 250mg Mfg: Cipla Pack: 120 tablets in a container Classified as: Anti-neoplastic agent Prescribing information of Xbira The most important indication of  xbira 250mg tablet   is; Metastatic castration resistance prostate cancer Metastatic high risk c...

Erlonat 150 mg - Erlotinib Natco tablet Price, Cost India

Drug profile   erlonat    is a Natco pharma item which is containing a functioning substance known as Erlotinib, a first line medication of decision in metastatic phase of non little cell lung tumor. erlonat  150mg  is normally endorsed for the patients who are not counters to less than one chemotherapy regimen. erlonat  150mg tablet  is synthetically described as quinazoline subordinate, with hostile to neoplastic impact against tumor cells. erlonat   is pharmacologically arranged as tyrosine kinase inhibitor. erlonat  150mg    is altogether raising the serum aminotransferase levels amid the treatment and this may causes liver wounds. erlonat  150mg tablet    tablets are containing 150mg of Erlotinib as a hostile to tumor specialist. PRODUCT DETAILS Brand name:  Erlonat    Active constituent: Erlotinib Strength: 150MG Mfg: Natco pharma Pack: 30 tablets per container Catego...